Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
83.94
+0.04 (+0.05%)
Official Closing Price
Updated: 4:15 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
34
35
Next >
Gilead Sciences' Debt Overview
March 22, 2023
Via
Benzinga
A Bull Market Is Coming: Load Up On These 3 Cheap Stocks Today
March 22, 2023
These stocks are all trading at less than 12 times their future profits.
Via
The Motley Fool
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
March 22, 2023
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via
News Direct
Exposures
Product Safety
Gilead's Flagship CAR T-cell Therapy Shows Improved Overall Survival In Pretreated Lymphoma Patients
March 21, 2023
Via
Benzinga
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
March 21, 2023
Successful Autologous Cell-Based Therapies
Via
Benzinga
Gilead Exercises First License Option Under Agreement With Nurix Therapeutics
March 20, 2023
Via
Benzinga
Gilead Sciences Unusual Options Activity
March 17, 2023
Via
Benzinga
A Look Into Gilead Sciences' Debt
March 06, 2023
Via
Benzinga
Peering Into Gilead Sciences's Recent Short Interest
March 06, 2023
Via
Benzinga
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
March 20, 2023
With the COVID pandemic still ongoing, having claimed more than 6.8 million lives from about 758 million cases and crippling the global economy, there are several reasons why drug research and...
Via
Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Via
InvestorPlace
Drug Companies Raising Prices Greater Than Inflation? US Government Mulling Imposing Fines
March 15, 2023
Under Joe Biden's signature Inflation Reduction Act, drugmakers for twenty-seven drugs will be penalized for charging prices that rise faster than inflation for people with disabilities or the elderly...
Via
Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks Delivering High-Dividend Yields
March 10, 2023
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
Analyst Expectations for Gilead Sciences's Future
March 06, 2023
Via
Benzinga
3 Stocks to Buy Right Now That Are Cash Cows
February 25, 2023
If cash is king, these three stocks should wear crowns.
Via
The Motley Fool
Why Shares of MacroGenics Jumped Thursday
March 09, 2023
The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy.
Via
The Motley Fool
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
March 08, 2023
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Via
News Direct
Topics
Economy
Exposures
Supply Chain
2 Healthcare Stocks That Could Help Set You Up for Life
March 07, 2023
Even seemingly boring businesses can deliver solid returns over long periods.
Via
The Motley Fool
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
March 07, 2023
Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics.
Via
Benzinga
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
March 06, 2023
Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD.
Via
Talk Markets
If You Invested $100 In This Stock 20 Years Ago, You Would Have $2,100 Today
February 17, 2023
Via
Benzinga
Elliott Wave Technical Analysis: Gilead Inc.
February 16, 2023
Looking for a clear three wave move in wave (ii) to then place longs.
Via
Talk Markets
7 Cash-Rich Companies to Invest in During Economic Uncertainty
February 26, 2023
Although they’re not necessarily the most exciting enterprises, these cash-rich stocks should keep your portfolio upright.
Via
InvestorPlace
GSK/Pfizer-Backed ViiV Healthcare's HIV Treatment At Par With Gilead's: Study Shows
February 23, 2023
Via
Benzinga
This Recession-Proof Company Has a Best-in-Class Dividend
February 22, 2023
Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group.
Via
The Motley Fool
Lattice Semiconductor To Rally 33%? Here Are 10 Other Analyst Forecasts For Tuesday
February 14, 2023
Goldman Sachs boosted the price target for Kaiser Aluminum Corporation (NASDAQ: KALU) from $70 to $80. Goldman Sachs analyst Emily Chieng maintained a Sell rating on the stock. Kaiser Aluminum shares...
Via
Benzinga
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
February 13, 2023
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends.
Via
Talk Markets
ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood
February 13, 2023
Why does Wall Street hate Cathie Wood and her ARKK ETF? Seven words show how her focus on innovation divides investors.
Via
InvestorPlace
Kite's Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings
February 09, 2023
Kite, a Gilead Sciences Inc (NASDAQ: GILD) company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel).
Via
Benzinga
2 Biotech Stocks That Could Make You Richer
February 09, 2023
Patience will pay off with these two stocks.
Via
The Motley Fool
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
34
35
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.